Friday, October 16, 2026

BMO Exit From AIR MILES Could Cut Loyalty Program Revenue 15-25% by 2027

Bank of Montreal's shift away from AIR MILES to a proprietary loyalty program threatens to reduce the Canadian program's transaction volume by up to a quarter over the next two years. The move directly impacts Diversified Royalty Corp, which owns AIR MILES through AM Royalties Limited Partnership and depends on transaction-based royalty streams.

BMO Exit From AIR MILES Could Cut Loyalty Program Revenue 15-25% by 2027
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Bank of Montreal announced January 26, 2026 its transition from AIR MILES to a new in-house loyalty program, a shift analysts project will cut AIR MILES' market share in Canadian loyalty programs by 15-25% through 2027.

Diversified Royalty Corp owns AIR MILES Reward Program through AM Royalties Limited Partnership. BMO serves dual roles as both an AIR MILES customer and guarantor of the partnership, making this departure financially material. The bank's exit removes a major transaction generator from a royalty-based revenue model.

The timing coincides with multiple partnership amendments and contract awards filed January 26, suggesting accelerated contract restructuring. These filings indicate AIR MILES is renegotiating relationships as it faces losing one of Canada's five largest banks.

Loyalty program economics depend on transaction volume. When major partners exit, remaining partners must compensate for lost activity or the program faces margin compression. AIR MILES collects royalties on transactions flowing through its network—fewer BMO credit card swipes and banking interactions mean lower royalty payments to Diversified Royalty Corp.

Canadian loyalty program consolidation has accelerated since 2020. Banks increasingly prefer proprietary programs that capture 100% of customer data and avoid sharing economics with third-party platforms. BMO's move follows a pattern where financial institutions calculate that direct customer relationships justify the cost of building loyalty infrastructure.

Diversified Royalty Corp investors should monitor Q1-Q4 2026 earnings for AIR MILES segment performance. Key metrics include program enrollment trends, redemption volumes, and revenue per active member. The company must disclose material changes to partnership agreements that affect royalty calculations.

The loyalty program market shows clear bifurcation: large financial institutions building proprietary systems versus retailers and smaller banks relying on established platforms like AIR MILES. BMO's departure tests whether multi-sponsor programs can maintain economics when anchor partners leave.

Air Miles Loyalty Inc operates the program infrastructure while AM Royalties Limited Partnership holds the intellectual property generating royalty streams. This structure means Diversified Royalty Corp faces revenue pressure without operational control over member retention strategies.

Quarterly tracking of BMO customer migration rates to the new program will determine whether the 15-25% revenue impact estimate holds. Fast migration accelerates AIR MILES revenue decline; slow migration provides time to replace lost volume with new partnerships.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com